Henlius Raises Stakes In Denosumab Race With Phase I Completion
HLX14 Denosumab Biosimilar Scores PK Trial Win; Submissions Expected Later This Year
Shanghai Henlius Biotech announced the successful completion of a Phase I study of its biosimilar HLX14 to Prolia/Xgeva, paving the way for EU and US approval applications later in 2024.
You may also be interested in...
Sandoz has truly established its position as the frontrunner in the denosumab race after a Canadian approval, but the path to the US market has been hindered by a lawsuit from the originator Amgen.
Alvotech has reported the latest clinical trial results for its AVT03 proposed denosumab biosimilar rival to Prolia and Xgeva.
Completion of the Phase III trial may lead Boan Biotech to international registrations of denosumab, a market worth over $5.6bn globally.